BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
Ella Day | August 19, 2025 | News story | Mergers and Acquisitions, Research and Development | BioMed X, Novo Nordisk, Pharmacy, drug development, therapeutic peptides
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of therapeutic peptides – a major challenge in drug development. The initiative, launched at BioMed X’s Heidelberg institute, Germany, will establish a research team focused on developing innovative oral formulation technologies.
The project, “Prolonged Retention of Oral Peptide Formulations in the Gut”, aims to enable site-specific, extended retention of tablets or capsules in the lower small intestine. This could significantly improve absorption and bioavailability, overcoming ongoing barriers such as low intestinal permeability and rapid gastrointestinal transit. By enhancing delivery efficiency, the work could lead to better patient compliance and expanded use of peptide-based therapies.
“We are excited about this new partnership with Novo Nordisk,” said Christian Tidona, CEO of BioMed X. “Making peptide drugs such as GLP-1 receptor agonists orally available via new formulation technologies will have a significant impact on patients’ lives.”
“We are excited about the opportunities that this project may bring,” added Stephen Buckley, scientific vice president at Novo Nordisk.
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut. Danish pharma company, Novo Nordisk, works to treat chronic illnesses.
Ella Day
19/8/25
Related Content
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …
